Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7097637 | 0.89 | BRD4 (0.32) | NR3C1PTGS1PDE10A | |
| SCHEMBL5239494 | 0.82 | KEAP1 (0.47) | NR3C1PTGS1KEAP1NFE2L2 | |
| SCHEMBL7248476 | 0.77 | BRAF (0.34) | PDE10A | |
| SCHEMBL7103450 | 0.77 | BRD4 (0.31) | PDE10A | |
| SCHEMBL7099288 | 0.74 | MAPT (0.43) | NR3C1PTGS1KEAP1NFE2L2 | |
| SCHEMBL5204050 | 0.74 | ADRA1A (0.42) | NR3C1PTGS1 | |
| SCHEMBL7149258 | 0.73 | ALDH1A1 (0.39) | NR3C1PTGS1KEAP1NFE2L2PDE10A | |
| SCHEMBL7100325 | 0.72 | NR3C1 (0.37) | NR3C1 | |
| SCHEMBL7248382 | 0.71 | NR3C1 (0.41) | NR3C1PDE10A | |
| SCHEMBL5200544 | 0.71 | ADRA1A (0.48) | NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | NR3C1 1807/4885PTGS1 467/4885CYP19A1 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.